International Journal of Clinical Research

Objective To investigate the effect of prolonged intravenous infusion time of meropenem on the efficacy and safety of patients with severe infection. Methods: From February 2020 to February 2021, 60 patients with severe infection in our hospital were retrospectively selected, and they were divided into the extended group and the routine group according to the intravenous infusion time of meropenem, with 30 cases in each group. Laboratory physical and chemical indicators, SOFA score, clinical efficacy, adverse reactions. Results: Before medication, the differences in body temperature, PCT level, WBC, and SOFA scores between the two groups were not significant (P>0.05). The routine group (P<0.05); the body temperature, PCT level, WBC and SOFA scores of the two groups of patients after treatment were lower than those before treatment (P<0.05). The total effective rate of the patients in the extension group was 80.00% (24/30), which was higher than that in the conventional group, which was 53.33% (16/30) (χ2=4.800, P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups, 26.67% (8/30) and 23.33% (7/30) (χ2=0.089, P<0.05). Conclusion: Prolonging the intravenous infusion time of meropenem in the treatment of severe infection patients can further improve the efficacy and safety of the treatment.

Severe Infection; Prolonged Intravenous Infusion Time of Meropenem; Effectiveness